HLB: full-scale US commercialization of bile duct cancer drug under way…liver cancer drug approval also accelerating
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
US commercialization and guideline inclusion were already reported; medium lowered to low.